Case Study – Advancing Precision Diagnostics with NGS at Hospital Italiano de Buenos Aires (HIBA), Argentina

Client

Hospital Italiano de Buenos Aires (HIBA) – Sequencing Laboratory
A leading healthcare institution in Argentina, recognized for hospital innovation, clinical genomics, and genomic diagnostics transformation in Argentina.
This initiative forms part of a next-generation sequencing collaboration case study, illustrating how NGS implementation in Latin American hospitals is reshaping molecular diagnostics and precision medicine in the region.

Objective

To transform diagnostic capabilities by implementing NGS technology through a Thermo Fisher Scientific NGS partnership to:

• Improve genomic testing quality and accuracy
• Reduce dependency on external sequencing providers
• Enable precision oncology genomic testing success and local innovation
• Generate local genomic data generation initiative for evidence-based clinical decision-making

HIBA aimed to achieve hospital laboratory modernization with NGS and to democratize access to advanced healthcare genomics within Latin America healthcare, fostering long-term impact in the regional diagnostic genomics ecosystem.

What We Did

HIBA’s sequencing collaboration with Thermo Fisher Scientific represented a strategic hospital-industry collaboration NGS initiative designed to advance research diagnostics and enhance clinical sequencing capabilities.

Key measures included:
• Deploying cost-effective sequencing and scalable sequencing technology in healthcare via Thermo Fisher partnership platforms such as Oncomine and Ion AmpliSeq panels
• Standardizing NGS workflow and quality to align with international best practices
• Accelerating clinical research and genomic data analysis through efficient genomic assay design and validation
• Transitioning in-house DNA sequencing tools to optimize turnaround times and reduce dependency on external vendors

The partnership delivered robust, cost-effective NGS adoption in developing healthcare, fostering a sustainable model for in-vitro diagnostics innovation in Latin America.

How We Did It

Technology Selection & Deployment

• Adopted NGS technology using Thermo Fisher’s Oncomine and Ion AmpliSeq panels, demonstrating hospital-led genomics capability building case success.
• Ensured broad application across oncology sequencing and clinical genomics, enabling precision medicine in Argentina diagnostics.

Analytical Validation & Regulatory Alignment

• Collaborated with Thermo Fisher’s Analytical Validation (AV) team, establishing a benchmark NGS analytical validation process case study aligned with global standards.
• Developed a robust clinical genomics validation workflow Argentina framework to ensure reliability and compliance.

Laboratory Modernization & Efficiency

• Achieved full laboratory modernization by integrating automation, digital reporting, and healthcare genomics tools.
• Enhanced cross-disciplinary collaboration to integrate genomic testing into clinical workflows, driving integrating NGS for clinical research efficiency.

Outcome

This NGS healthcare adoption initiative unlocked major advancements in precision medicine and hospital innovation:

• Expanded access to high-quality genomic data and clinical sequencing for oncology and research.
• Lowered costs compared to outsourcing, exemplifying cost-effective NGS adoption in developing healthcare.
• Improved turnaround times and productivity through NGS validation and automation.
• Strengthened compliance with international in-vitro testing
• Elevated HIBA’s reputation as a regional leader in genomic diagnostics transformation in Argentina.

The project became a hallmark Thermo Fisher Scientific NGS partnership, reinforcing global standards for healthcare genomics excellence and precision oncology genomic testing success.

Client Actions

Following the successful sequencing collaboration, HIBA genomics expanded its reach and impact:
• Broadened genomic testing portfolios aligned with emerging oncology sequencing needs.
• Strengthened clinician-researcher collaborations to expand patient access to molecular diagnostics.
• Positioned itself as a model for hospital-led genomics capability building case in Latin America.
• Advanced research diagnostics partnerships, contributing to regional genomic data analysis initiatives.
• Continued investment in healthcare genomics infrastructure and NGS workflow scaling to meet future precision medicine demands.

This next-generation sequencing collaboration case study exemplifies how NGS implementation in Latin American hospitals, through Thermo Fisher Scientific NGS partnership, drives hospital laboratory modernization with NGS, genomic diagnostics transformation in Argentina, and a sustainable NGS analytical validation process case study framework.

It underscores how strategic hospital-industry collaboration NGS initiatives can transform Latin America healthcare — advancing clinical genomics, NGS validation, and precision medicine to achieve equitable, high-quality, and efficient genomic testing for the future of healthcare genomics.

Click Here : https://www.marketsandata.com/industry-reports/in-vitro-diagnostics-market